Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ReSoMal is an **oral rehydration solution (ORS) powder** specifically formulated for the prevention and treatment of dehydration in **children with severe acute malnutrition (SAM)**. Unlike standard ORS, ReSoMal contains **lower sodium (45 mmol/L) and higher potassium (40 mmol/L)** concentrations, along with additional minerals such as magnesium, zinc, and copper, to meet the unique electrolyte requirements of severely malnourished patients[1][5][8]. It must be diluted in clean water before use and is administered **orally or via nasogastric tube** under medical supervision in clinical settings. Its use is restricted to children (typically 6–59 months old) with SAM and should not be used in well-nourished individuals or cholera patients, as its sodium content may be insufficient in cases of high sodium loss[1][3][8]. The product is primarily intended for use in **therapeutic feeding centers** and not for home administration. The main risks associated with ReSoMal include fluid overload and hyponatremia, so careful monitoring during administration is essential[3][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ReSoMal.